Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

Novo Nordisk has made a bold $9 billion bid for Metsera, a US biotech firm specializing in obesity treatments, potentially outbidding Pfizer's earlier offer of $7.3 billion. This move highlights the intense competition among pharmaceutical giants to dominate the lucrative weight-loss market, especially given Metsera's promising pipeline of drugs. As obesity rates continue to rise globally, advancements in effective treatments are crucial, making this acquisition significant for both companies and the healthcare landscape.